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Abstract
Background: Perindopril, a long-acting angiotensin converting enzyme-inhibitor, reduces
incidence of cardiovascular end points in a wide range of patients. This effect depends on both
the antihypertensive and blood pressure lowering unrelated effects. The aim of the study was to
check the possible influence of patients' clinical profile on the antihypertensive efficacy of
perindopril.
Methods: A meta-analysis of individual data of hypertensive patients enrolled in five open
studies tested the efficacy and safety of perindopril over a 12-week treatment period.
Results: We included data of 3,188 men (39%) and women, aged on average 53 years, whose
baseline systolic/diastolic blood pressure averaged 163/99 mm Hg and on average declined by
27/17 mm Hg. Mean duration of hypertension was five years, and 34% of patients had prior
cardiovascular complications. We found no difference in the antihypertensive effect of perindo-
pril in patients with complicated vs non-complicated hypertension (DSBP 0.05, 95%CI:
–1.5 to 1.6 mm Hg, p = 0.95), in older vs younger patients (DSBP 2.4, 95%CI: –3.2 to 7.9 mm Hg,
p = 0.41), in men vs women (DSBP –1.43, 95%CI: –3.4 to 0.5, p = 0.15), and in patients
with long-lasting vs shorter duration of hypertension (DSBP 0.0, 95%CI: –1.0 to 1.0 mm Hg,
p = 1.0). The antihypertensive effect of perindopril was stronger in patients with greater
(≥ 160 mm Hg) systolic blood pressure (DSBP 12.3, 95%CI: 5.5 to 19.0, p = 0.0004). The
effect on diastolic blood pressure tended to be greater in younger patients (DDBP –0.63, 95%CI:
–1.2 to –0.02 mm Hg, p = 0.04).
Conclusions: Perindopril is an effective antihypertensive medication. Its efficacy seems not to
be adversely affected by the clinical profile of the patient. (Cardiol J 2010; 17, 3: 259–266)
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Introduction
What is known on the topic? Blood pressure
reduction translates into improvement of cardiovas-
cular prognosis in hypertensive patients. The an-
giotensin converting-enzyme inhibitor perindopril
is a potent antihypertensive drug. Accordingly, it
reduces the cardiovascular risk both in primary and
secondary prevention setting. However, due to the
prerequisites of the way clinical trials are conduct-
ed, most of the studies that prove this have been
performed in highly selected groups of patients,
whose clinical characteristics usually differ from
those encountered in regular practice.
What this article adds? Building on a large
pool of individual patient data from studies per-
formed in a regular outpatient setting, this paper
attempts to check whether the antihypertensive
effect of periondopril could be influenced by such
characteristics as gender, age, baseline systolic
blood pressure (SBP), duration of hypertension and
history of cardiovascular disease. We found the
short-term antihypertensive effect of perindopril to
be universal, largely independent of the studied
characteristics.
Hypertension is the predominant risk factor for
developing cardiovascular complications world-
wide [1, 2], both in primary prevention setting and
in patients with coronary artery disease and cere-
brovascular disease [3]. Cardiovascular risk associat-
ed with hypertension can be minimised by adequate
antihypertensive treatment [4, 5]. Although some
drug classes, angiotensin-converting enzyme inhi-
bitors (ACE-I) in particular, express their beneficial
effect through properties extending beyond their
effect on blood pressure, in hypertensive subjects
it is the reduction of blood pressure which is respon-
sible for most of the protective effect [6]. Howev-
er, the extent to which the antihypertensive effect
depends on patients' characteristics such as base-
line blood pressure level, sex, age, and history of
cardiovascular complications, has not been suffi-
ciently studied.
In recent years, the results of large-scale tri-
als have been published, showing that perindopril,
a long-acting ACE-I, is very potent in reducing the
risk of recurrent stroke [7] or new cardiovascular
complications in high risk patients [8]. However,
patients recruited in the framework of clinical tri-
als usually form a highly selected population.
Based on individual patient data obtained from
unselected groups of hypertensive patients, we
aimed to check to what extent blood pressure can
be lowered during short-term treatment with es-
calated doses of perindopril, and whether this blood
pressure reduction would be influenced by clinically
relevant characteristics of the patient.
Methods
Data acquisition
We included individual patient data accumulat-
ed in the framework of five open-label, multicenter
studies performed in Poland between 1994 and
2003. The protocols of the studies were in accor-
dance with the regulations of clinical study conduct
in operation at the time the respective studies be-
gan. All patients gave informed consent and were
subsequently treated with an open label active an-
tihypertensive drug in accordance with its registra-
tion characteristics. All trials were supported by
unrestricted research grants from Servier Poland,
and were carried out by independent clinicians un-
der the supervision of experts in the field of hyper-
tension with high academic and clinical profiles.
After the respective databases had been closed, the
data were analyzed and published in a range of Po-
lish medical journals. Subsequently, the data were
stored by Servier Poland in the MS Excel format. In
order to perform the current analysis, the data were
converted into SAS format. The subsequent clean-
ing, merger, management, and analyses of data, were
performed by one of the authors (J.G.) using SAS 9.1
software, independently of Servier Poland.
Subgroup definition and
selection of outcome measures
We defined the subgroups in which we tested
the short-term antihypertensive efficacy of perin-
dopril as 'progressors' and 'non-progressors' (pa-
tients who at the end of respective studies were
receiving 8 and 4 mg of perindopril per day, respec-
tively), non-complicated and complicated hyperten-
sion (history of one or more of the following: coro-
nary artery disease, myocardial infarction, stroke,
and heart failure), older or younger then median age
in the total population, sex, SBP of less than or of
160 mm Hg and more, shorter or longer (than pop-
ulation median) duration of hypertension. As a pri-
mary outcome measure, we chose the treatment-
induced change in SBP. As a secondary outcome
measure, we used the treatment-induced change in
diastolic blood pressure (DBP).
Statistical analysis
We used the SAS software package (SAS In-
stitute, Cary, NC), version 9.1, and Review Man-
ager 4.2 (Cochrane Collaboration, Copenhagen,
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Denmark), for database management and statisti-
cal analysis. We compared means and proportions
by the standard normal z-test and the c2-statistic,
respectively. Using random effects modeling, we
calculated the net difference in blood pressure lo-
wering effect according to defined subgroups. The
heterogeneity was checked using Zelen's test
(based on c2 distribution) and I2 statistic. I2 of more
than 50% was considered to indicate significant
heterogeneity of the effect across studies. The time
trends of blood pressure change from baseline and
the time subgroup interaction were checked using
the ANOVA models, as implemented in the PROC
GLM procedure of SAS software. In cases of sig-
nificant heterogeneity across studies, the influence
of a characteristic on studied outcome was checked
using ANOVA models with adjustment for respec-
tive study.
Results
Characteristics of studies
In the analysis, we included individual data of
3,188 patients enrolled in five open-label studies
which assessed the efficacy and tolerability of 2 to
8 mg of perindopril daily. The main characteristics
of the studies are presented in Table 1. The two
largest studies were the Perindopril Assessment
Study phase 1 and 2 (PAS12), performed between
1994 and 1996 [9]. The studies were performed
according to the same protocol and the databases
were pooled soon after their completion, and there-
fore are considered jointly. The inclusion criteria
were based on the level of DBP. Included were con-
secutive outpatients or newly diagnosed untreated
hypertensives, whose DBP was in the range be-
tween 90 to 110 mm Hg. The treatment period of
the study lasted for 15 weeks. The data of 1,806 pa-
tients (out of a total 2,038), were available for the
present analysis. The Perindopril Assessment
Study 3 (PAS3) took place between 1997 and 1998
[10]. The blood pressure inclusion criteria were
based on elevation of SBP (140–179 mm Hg) and/or
DBP (90–99 mm Hg). To be included, the untreated
or uncontrolled hypertensives had to have body
mass index (BMI) of more than 30 kg/m2. The treat-
ment period of the study lasted 12 weeks. Of 391
enrolled, the data of 378 patients were available at
the end of follow-up and included in the present
analysis [10]. The Perindopril Assessment Study 4
(PAS4) was performed between 1998 and 1999 in
a group of 667 post-menopausal women [11]. The
blood pressure entry criteria were the same as for
the PAS3. After the 12 week treatment period, the
data of 622 patients were available for analysis. Fi-
nally, the Perindopril Assessment in Diabetes Study
Table 1. Characteristics of patients.
Characteristic PAS12 PAS3 PAS4 PADS All
(n = 1806)  (n = 378)  (n = 622)  (n = 379)  (n = 3188)
Sex — male (%) 49.3 47.6 0 45.8 39.0
Age (years) 51.6 ± 10.6 50.0 ± 9.2 54.8 ± 5.4 55.9 ± 8.2 52.5 ± 9.5
HT duration (years) 5.8 ± 5.3 4.1 ± 4.9 3.6 ± 4.7 5.3 ± 5.2 5.1 ± 5.3
BP [mm Hg]:
Baseline SBP 168.0 ± 17.7 161.6 ± 10.0 161.9 ± 9.3 148.5 ± 6.1 163.7 ± 15.8
Follow-up SBP 140.3 ± 13.9 136.5 ± 10.1 136.3 ± 9.9 124.5 ± 8.4 137.2 ± 13.2
DSBP 27.7 ± 18.4 25.1 ± 12.2 25.6 ± 11.0 24.0 ± 10.0 26.5 ± 15.7
Baseline DBP 101.7 ± 8.5 99.3 ± 5.2 98.3 ± 5.3 90.2 ± 4.7 99.4 ± 8.1
Follow-up DBP 85.6 ± 8.4 83.6 ± 6.3 82.2 ± 5.8 77.9 ± 5.7 83.8 ± 7.8
DDBP 16.1 ± 10.6 15.6 ± 7.6 16.6 ± 6.9 12.3 ± 6.6 15.6 ± 9.3
Complications (%): 41.5 30.7 28.0 15.0 34.4
CAD 9.5 8.7 9.6 9.2 9.4
MI 1.8 0 0.5 1.3 1.3
HF 1.1 0 0 0.3 0.6
ST 0.6 0 0.3 0.8 0.5
Dose of perindopril 5.0 ± 1.8 4.8 ± 2.1 5.4 ± 2.2 5.4 ± 2.1 5.1 ± 2.0
at follow-up
Indapamide (%) 13.7 7.9 13.4 10.3 12.5
Plus-minus values are non-weighted mean ± standard deviation; HT — hypertension; BP — blood pressure; SBP — systolic blood pressure,
DBP — diastolic blood pressure; D — difference between baseline and follow-up; CAD — coronary artery disease; MI — myocardial infarction;
HF — heart failure; ST — stroke
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(PADS) was performed between 2002 and 2003 in
400 patients in whom diabetes mellitus had been
diagnosed at least three months prior to inclusion,
and whose SBP values were in the range of 135 to
159 mm Hg, or whose DBP values were in the range
of 85 to 99 mm Hg [12]. After the treatment period
of 12 weeks, the data of 376 patients were available
for analysis.
In all studies, the included subjects were con-
secutive outpatients who met the entry criteria. In
all patients who after the run-in period of two weeks
met the criteria, treatment with perindopril 2 to
4 mg once daily was started. During consecutive
visits performed at four week intervals, the physi-
cians could raise the dose of perindopril (up to 8 mg
once daily) as judged necessary to achieve the pre-
defined blood pressure control. Only after the max-
imum dose of perindopril was reached  could the
physician in charge introduce the second-line drug,
a thiazide-like diuretic indapamide (2.5 mg standard
release, or 1.5 mg sustained release preparation,
once daily). In patients whose blood pressure was
uncontrolled despite receiving the maximal treat-
ment as provided for in the protocol of the study,
or in whom there were compelling indications for
other treatments or for withdrawal from the study,
the protocol-based treatment was stopped and the
appropriate action taken (Table 1). In four studies,
the target was the DBP of less than 90 mm Hg. In
the PADS, the target was blood pressure of less
than 135/80 mm Hg.
Characteristics of patients
Except in the one study (PAS4) which includ-
ed only women, the percentage of men was 45.8 to
49.3, and overall, women predominated in the
pooled database (61.0%). Mean age of the analyzed
subjects ranged from 50.0 to 55.9 years and aver-
aged (weighted for the size of study) 52.1 years.
A total of 1,501 (47.1%) patients were older than
the median age of 53.0 years. The average duration
of hypertension was 5.1 ± 5.3 years. In 1,503 (47.2%)
patients, the duration of hypertension was longer
than the overall group median of 3.4 years. At base-
line, 1,098 (34.4%) patients had complications of
hypertension. In 2,014 (63.2%) patients, the base-
line SBP was higher than 160 mm Hg. The average
dose of perindopril at the end of the treatment pe-
riod was 5.1 mg (range 2–8). At that time, 2,092
(65.6%) patients were receiving 4 mg of perindopril
once daily (dose non-progressors) and 923 (29.0%)
were treated with 8 mg of perindopril once daily (dose
progressors). At the end of follow-up, 400 (12.6%)
patients were additionally receiving indapamide. The
doses of 2 and 6 mg were received by 61 (1.9%) and
41 (1.3%) patients respectively. In 71 (2.2%) patients
the protocol-based treatment was stopped at the last
visit. The goal level for systolic, diastolic or both blood
pressures was achieved in 53.5%, 68.6%, and 43.9%
of patients, respectively (Table 1).
Blood pressure lowering in
dose progressors and non-progressors
The baseline SBP and DBP was significantly
higher (p < 0.0001) in 613 patients who in the
course of a study required an increase in the dose
of perindopril to 8 mg, and were not concomitantly
treated with indapamide (progressors, 165.8 ± 16.2/
/100.7 ± 8.0 mm Hg) as compared with 2,016 pa-
tients who at the end of a study were treated with
perindopril 4 mg, without additional indapamide
(non-progressors, 162.0 ± 15.3/98.5 ± 7.9 mm Hg).
At the end of the 12 week treatment phase, the
SBP and DBP in progressors (138.8 ± 12.5/84.8 ±
± 7.6 mm Hg) were higher (p < 0.0001) than in non-
-progressors (135.1 ± 12.3/82.5 ± 7.2 mm Hg).
Using the multivariate ANOVA approach, with ad-
justment for trial allocation, we found that the time-
-course of blood pressure decrease was faster in pro-
gressors and that the progression to 8 mg was as-
sociated with a higher degree of net blood pressure
change (all p < 0.0001). At first, second and last fol-
low-up visits the net blood pressure differences of
SBP from baseline, in progressors minus non-progres-
sors (95%CI, p) were: –6.9 (–7.5 to –6.9, p < 0.0001),
–1.5 (–2.0 to –0.9, p = 0.03) and 0.2 (–0.3 to 0.8,
p = 0.68), respectively. For the rest of the analy-
ses, we considered the patients' data irrespective
of the dose progression status.
Blood pressure lowering
according to clinical profile
Using the random effects model for continuous
outcome measures as implemented in the Review
Manager version 4.2 (Cochrane Collaboration), we
checked whether the antihypertensive effect of
perindopril was influenced by patients' clinical pro-
file. We performed this analysis for five pre-defined
clinical characteristics: complicated vs non-compli-
cated hypertension, long vs short duration of hy-
pertension, men vs women, older vs younger, and
with or without elevation of SBP above 160 mm Hg.
To do that, for each of the subgroups, and in each
study separately, we calculated the blood pressure
difference ( standard deviation) between last and first
visit during the treatment phase. We also checked
for the possible heterogeneity of the effect across
the trials using the Zelen's test and I2 statistic.
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Overall, there was no difference in the antihy-
pertensive effect of perindopril in patients with
complicated hypertension as compared to those
without complications (DSBP 0.05, 95%CI: –1.5 to
1.6 mm Hg, p = 0.95, I2 = 49.1%, Fig. 1), in older
compared to younger patients (DSBP 2.4, 95%CI:
–3.2 to 7.9 mm Hg, p = 0.41, I2 = 97.2%, Fig. 2), in
men compared to women (DSBP –1.43, 95%CI:
–3.4 to 0.5, p = 0.15, I2 = 61.3%, Fig. 3), and in pa-
tients with long-lasting compared to shorter dura-
tion of hypertension (DSBP 0.0, 95%CI: –1.0 to
1.0 mm Hg, p = 1.0, I2 = 0%, Fig. 4). When the
elevation of SBP (≥ 160 mm Hg compared with
< 160 mm Hg) was considered, the antihyperten-
sive effect of perindopril was stronger in the group
with SBP ≥ 160 mm Hg (DSBP 12.3, 95%CI: 5.5 to
19.0, p = 0.0004, I2 = 97.5%, Fig. 5).
For age, sex and SBP elevation classes
(I2 greater than 50%), we repeated the analysis using
the multivariate ANOVA with adjustment for trial
allocation. For age and SBP groups it yielded con-
firmatory results (the p values for the class time
Figure 1. Comparison 1. Complicated versus non-complicated hypertension (HT).
Figure 2. Comparison 2. Older versus younger patients.
Figure 3. Comparison 3. Women versus men.
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interaction and the between-subject overall trend
differences of 0.89 and 0.63, respectively, for age,
and 0.0001 and 0.0001 respectively, for SBP). For
sex classes, the analysis showed a significant be-
tween-subject difference in achieved blood pressure
reduction favouring women (adjusted DSBP –2.7,
95%CI: –2.9 to 2.5, p = 0.004); however, there was
no influence of sex class on the time-related slope
of SBP decrease (p = 0.30). The effect of treatment
with perindopril on DBP was influenced by age. In
younger patients, there was a significant trend
for greater effect (DDBP –0.63, 95%CI: –1.2 to
–0.02 mm Hg, p = 0.04, I2 = 0%). Likewise, in patients
with baseline SBP equal or higher than 160 mm Hg
(with mean baseline DBP of 102.2 ± 7.2 mm Hg),
compared to patients with SBP lower than 160 mm Hg
(baseline DBP 94.5 ± 7.3 mm Hg), the effect of treat-
ment with perindopril on DBP was greater (adjusted
DDBP –4.5, 95%CI: –5.2 to –7.6 mm Hg, p < 0.0001).
Discussion
Our meta-analysis of individual patient data
demonstrates that perindopril, an ACE-I, efficiently
reduces blood pressure in patients irrespective of
their main clinical characteristics. This blood pres-
sure-lowering effect is not substantially altered by
the presence of complications, age, sex, or duration
of hypertension. The effect is more pronounced in
patients with higher SBP values. The slope of the
decrease of blood pressure is steeper in patients
who progress to higher doses of perindopril. How-
ever, both progressors and non-progressors achieve
substantial blood pressure reductions.
Perindopril was shown to be an effective anti-
hypertensive agent. In essential hypertensive pa-
tients, it is capable of reducing blood pressure by
22/11 mm Hg, SBP and DBP, respectively [13]. It
was shown to be non-inferior in this capacity to pla-
cebo [13], and a range of antihypertensive medica-
tions, including beta blockers [14, 15], diuretics
[16], and other angiotensin converting enzyme in-
hibitors [17]. On the other hand, treatment with
perindopril was shown to be safe, even in patients
with mild or no elevation of blood pressure [18].
The issue of the antihypertensive efficacy of
perindopril in a large population of hypertensive
patients has been addressed in a large practice-
based study carried out in the USA [19]. The study,
which included more than 13,000 patients, showed
that on average, perindopril reduced blood pressure
from 156.9/84.5 mm Hg to 139.2/84.0 mm Hg. In
line with this observation, we showed a similar de-
gree of blood pressure lowering effect associated
Figure 5. Comparison 5. Higher versus lower systolic blood pressure (HT).
Figure 4. Comparison 4. Long versus short duration of hypertension (HT).
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with up-to 12 week treatment with perindopril. In
a series of further sub-studies, the investigators
showed that perindopril effectively reduces blood
pressure in patients with cardiovascular disease,
isolated systolic hypertension and patients with
previously refractory hypertension [20]. Contrary
to some reports from smaller studies [21], the in-
vestigators also showed that it is likewise effica-
cious in older hypertensive patients [22]. In our
meta-analysis, we were able to confirm and extend
these findings. We demonstrated that perindopril
is equally effective in patients with and without car-
diovascular complications. We also showed that it
tends to be more effective in patients with higher
SBP. However, neither age nor sex nor duration of
hypertension influenced its short-term antihyper-
tensive potency.
The present study must be interpreted within
the context of its limitations. Although the data we
used were collected uniformly, there were differen-
ces in protocol regarding the blood pressure criteria
for entry. One of the included studies recruited only
post-menopausal women ; another was performed
in obese hypertensives; and yet another one in dia-
betic patients with hypertension. This may have
influenced the blood pressure, responsiveness to
therapy, and prevalence of cardiovascular compli-
cations. Secondly, in our post-hoc analysis we cat-
egorised patients according to their clinical profile,
which was not provided for in the protocols of the
respective trials. The effect of the unadjusted anal-
yses of the effect of one characteristic on blood pres-
sure reduction, may contain an effect of another (i.e.
the effect of SBP may contain an effect of age). This
may (and for some clinical characteristics indeed
does) cause heterogeneity of the effect. However,
the repeated analyses using ANOVA with adjust-
ment for trial allocation give largely confirmatory
results. Lastly, the perindopril formulation used in
the included studies (4 mg tablets) differed from the
formulations currently available on the market
(5 mg and 10 mg tablets).
Conclusions
In conclusion, in a large cohort of mild-to-mo-
derate hypertensive patients, we confirmed that
perindopril is an effective blood pressure-lowering
medication, and in patients with higher SBP its po-
tency seems to be somewhat higher. The drug is
equally efficacious and safe in patients with and
without cardiovascular complications, women and
men, older and younger and those with either short
or longer duration of hypertension.
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